Member Info for MR.Spacetomato

Simbolca,

You asked if the share price is justified by the current company income? I would imagine if this was a car manufacturer, a bus operator or a banana farmer I would say you may have a point. But no, this company has in the pipeline the fastest and most sought after covid 19 antigen test worth when it hits the markets hundreds of millions at least.

But, that will be only spare change that will definitely help get us noticed and move us out of the AIM, not to mention help fund the cancer linked trials for the other uses of the affimer technologies; basically, AVACTA, all going well, will be propelled sky high in terms of valuation. The oncology wing of the business is the golden egg laying goose of this diamond of a company. We have geniouses working there.

I am very confident in what I have read and understood on the company website that I put all my pension and ISA into avct. I broke every rule I have on investment. That's my investment and I care not to what derampers may say here, they don't influence my decisions... my research does.

Good luck all.

ST

NoviceInvest, you forgot this one:

Sorry, we missed you. We left your affimers at the neighbourhood's next door.

themuir01, I was going to paste the exact paragraph. For me that's the best reason to remain a shareholder here for the long term. What a potential!

St

Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:

 

"Avacta has over the past few years created huge potential value for shareholders through the establishment of multiple global partnerships and a pipeline of Affimer therapeutics and diagnostics. On top of that, we have taken the therapeutics opportunity to the next level by adding the unique pre|CISION chemotherapy platform. The Company is now delivering this value to shareholders and is in a position to continue to do this in a long term and sustainable manner.

 

The planned phase I study of AVA6000 pro-doxorubicin in cancer patients is transformational for the Group. If the preclinical performance of this drug is recapitulated in humans, then not only will AVA6000 have the potential to become a proprietary blockbuster in its own right, but the potential of the pre|CISION platform to improve the safety of a range of chemotherapies will have been demonstrated. This is a significant and unique opportunity for the Group to address urgent clinical needs in oncology through advanced chemotherapies and in combination with Affimer immunotherapies. 

 

The strong commercial progress in the Affimer diagnostics business unit is reflected in the number of technology evaluations and growing revenue. Very recently a spotlight has been shone on the power of the Affimer platform to generate diagnostic reagents quickly and with high specificity because of our success in generating diagnostic Affimers for the SARS-COV-2 antigen in our collaboration with Cytiva.

 

We are focused on building long term, sustainable growth in shareholder value based on the numerous therapeutic and diagnostic opportunities that the Group has created, including a COVID-19 rapid antigen test. I look forward very much to keeping the market up to date as we progress."

 

- Ends -

Financial highlights

·    Initial up-front milestone payment of $2.5 million received from LG Chem Life Sciences.

·    Fundraising completed in November 2019 raising gross proceeds of £9.0 million in order to progress the AVA6000 programme into clinical trials.

·    Cash balances at 31 December 2019 of £8.8 million (31 July 2018: £5.2 million)

·    Revenues of £5.5 million for 17-month period to 31 December 2019 (12-month period to 31 July 2018: £2.8 million)

·    Operating loss of £18.0 million for 17-month period to 31 December 2019 (12-month period to 31 July 2018: £10.4 million)

·    Increased R&D investment, driven by strong progress in therapeutic programmes, leading to reported loss of £15.6 million (2018: £8.8 million)

·    Loss per ordinary share 13.0p (2018: 13.5p)

 

Post-period highlights: further therapeutic and diagnostic partnerships adding significant value to the Group

·   Established a joint venture in South Korea with Daewoong Pharmaceutical Co. Ltd., (KSX: 069620), a leading Korean pharmaceutical company, to develop the next generation of cell and genetherapies, incorporating Affimer proteins to enhance the immune-modulatory effects. Avacta's own research and development costs in relation to the joint venture will be paid for by the joint venture.

·   Paul Fry appointed as Non Executive Director. Paul is Chief Financial Officer of Vectura Group plc, an industry-leading inhaled drug delivery specialist listed on the FTSE Main Market.

·   Following a post-period end £5.75 million fundraising the business remains well capitalised with a £10.5 million net cash position as at the 30 April 2020.

·    Collaboration with Cytiva (formerly GE Healthcare Life Sciences) to develop and manufacture a rapid test for the COVID-19 coronavirus antigen for mass population screening.

·    Collaboration with Adeptrix to develop a high throughput Affimer-based antigen test to diagnose COVID-19 infection, to be used on hospitals' existing installed base of mass spectrometers.

·     Completed IND-enabling studies for first pre|CISION chemotherapy candidate - AVA6000 pro-doxorubicin. The Company is aiming to begin a Phase I dose escalation clinical trial in 2020 to show that the cardiotoxicity of this $1 billion global annual revenue generic drug is significantly reduced, potentially creating a proprietary, blockbuster chemotherapy for advanced soft tissue sarcoma, as well as other cancers, and validating the pre|CISION technology in humans.

·      An additional pipeline of more than ten pre|CISION chemotherapies has been established with the most advanced of these, a pre|CISION proteasome inhibitor, approximately 12 months from IND filing.

 

In-house Affimer therapeutic programmes: first candidate completes cell line development

·    Critical milestone of selecting the first Affimer clinical candidate for first-in-human trials for the Affimer platform has been achieved.  Initial GMP manufacturing steps for the AVA004-251 PD-L1 blocker clinical candidate have been successfully completed, confirming a high production yield from a routine manufacturing process.

 

Affimer diagnostics reagents: strong revenue growth and progress with partners towards licensing deals

·      Strong growth in revenue reported at £0.8 million for Affimer diagnostics reagents business.

·     Appointment of David Wilson, a diagnostics industry veteran with over 25 years of experience, as Commercial Director for Affimer diagnostics reagents.

·      Excellent range of ongoing paid-for technology evaluations and Affimer services projects with high-quality, global commercial partners across significant in vitro diagnostic, pharma, biotech and bioprocessing companies with potential for licensing deals.

·      Commercial licence agreed with New England Biolabs® (NEB®), a global leader in the discovery and production of enzymes for molecular biology applications.  This agreement is to commercialise a product using the Affimer technology for use in both life science research and diagnostics assays.  

·      A proprietary pipeline of Affimer diagnostic assays aimed at accelerating licensing deals has been established, with the first two, a D-dimer and an estradiol assay, having been completed.

Preliminary Results for the 17-month period ending 31 December 2019

 

Strong revenue growth and cash position and multiple major long term growth opportunities established

 

Significant progress post period end with two partnerships established to develop

Affimer-based COVID-19 antigen tests

 

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, is pleased to announce its preliminary results for the 17-month period ending 31 December 2019.

Operating highlights

 

LG Chem partnership: progressing well and expanding to new targets

·     Major therapeutics development partnership and licensing agreement with LG Chem Life Sciences (LG Chem).  Potentially generating revenues for Avacta of up to $310 million, plus future royalties on product sales, the agreement included an upfront payment of $2.5 million, pre-clinical milestone payments of up to $5.5 million plus payment of Avacta's full research costs to generate Affimer molecules for the treatment of a range of diseases. 

·      Excellent progress with initial target during 2019 has led to LG Chem expanding the collaboration and nominating the second and third targets for development.

 

Collaboration with ADC Therapeutics: partnership to develop Affimer-drug conjugates

·     Collaboration agreement with ADC Therapeutics SA (Lausanne, CH) to develop Affimer-drug conjugates combining Affimer technology with ADC Therapeutics' PBD warhead and linker technologies.  Under the terms of the agreement, ADC Therapeutics will cover all Avacta's research costs during the collaboration and Avacta will also receive certain fees, development and commercialisation milestones, as well as a royalty on sales of successfully developed products.

 

Partnership with Moderna Therapeutics: enters next phase as Moderna exercises commercial option 

·   Moderna Therapeutics Inc exercised its option to enter into an exclusive licensing agreement for Affimers against an undisclosed target; part of an ongoing research collaboration between the two companies.  A future regulatory submission by Moderna for an Affimer clinical candidate would trigger the next milestone payment to Avacta.

 

pre|CISIONTM chemotherapy platform: significant opportunity as "chemotherapy without side effects" and in novel Affimer drug-conjugates (TMACs)

·      Research collaboration and licensing agreement for chemistry developed at Tufts University Medical School has created the pre|CISION chemotherapy platform which is a new class of chemotherapies that are only activated in the tumour thereby improving the safety and tolerability of these effective anti-cancer drugs. 

·    Avacta's long-term strategy to build a pipeline of novel and differentiated cancer treatments is to combine pre|CISION chemotherapies with Affimer immunotherapies in TMACs to improve the outcomes for patients who do not respond to existing immunotherapies

Rapid,

Spot on!

ST

Damn,

Just ho to director's talk...Google it: Avacta Group CEO Alastair Smith discusses COVID-19 antigen test (Interview)

Ade1234,

Here, bed time story from our CEO. Itt is about our partnership with Adeptrix Corporation. Alastair explains how the test works, the benefits of this type of test compared to other lab tests, how long the test will take to develop and the route to market:

https://www.***************************/avacta-group-ceo-alastair-smith-discusses-covid-19-antigen-test-interview/412817915

Good dreams

St

RE: Goodnight

I see, Billy no mates?

Adel1234,

You are not invested here, and not invested in ncyt. What are you doing here and there posting?

Ade1234,

Posted on NCYT:

RE: Mad27 Apr 2020 15:34
"Some people don’t like hearing the truth.

I wish everyone good luck seriously, I just hope people last in don’t loose to much".

Honestly, you must be shirting yourself about what's going to happen once we hit the markets with American Novacyt produces the test kit and Trump will trumpet our game changer test!

And by the way, NCYT 90 minute is after one waited God knows how long for someone to collect the samples from you! Ours? You might be able to get at the newsagent together with some snickers and a pack of chewing gums!

And please, do your research on the 100% gold standard of our affimer technology.

But I give you one thing, it must be scary indeed witnessing the armageddon arriving!

St

O&W, thanks for the heads up. 50k at 600p will beat mine at 105.5. I just don't want to be pushed by MMS to be honest. :0/

37K at 105.5p is the max I want to offer to MMS.

32 million extra shares at 18p and these people cannot drop the price to 103.5! Come on!

Sorry, no deramper but can the negotiate on a quick sale at least?

:0/

Green23, they call it "projection " in psychopathology.

Kbiztbiz, I am a sheep in wolves clothing!

I just been told my SIPP fund will clear into my account on Monday. So, if you see £37.077.74 (minus costs) being spent on Avacta shares after the first 40 minutes of opening at say 102p a share (I live in hope, remember...a sheep still), well, that will be me.

Have a good weekend everyone.

ST

Good day everyone,

I used to like reading the posts here when informed investors would post their views based on research they did. I learned quite alot and also did alot of research on my own, which, more than anything else, helped make my mind up on whether I should buy in or not. I bought it whenever I could get hold of cash: at 48p, 50.25p, 59p, 93p and 110p. If I am lucky enough, I will have my SIPP funds available early next week at these levels. I am looking for long term. ;0)

I know some of you want a quick buck, in and out, and I couldn't care less, after all this is the aim market. But that will be short lived one of these days, and I would not be surprised we leave aim sooner.

For the moment, could we please try and bring some more mature discussions here? Or at least, we should not reply to some rubbish posted here sometimes?

Cheers.

ST

Thank you, RB40. Good round up.

ST